Figure 1.

Imaging examples: pre-treatment (Pre-Rx) 16 alpha-[¹⁸F]-fluoro-17 beta-estradiol positron emission tomography (FES PET; left) and ¹⁸F-fluorodeoxyglucose (FDG) PET (middle) scans and follow-up FDG PET post-therapy (Post-Rx; right) are shown. Dashed arrows show normal liver FES uptake. (a) This patient has bone metastasis with robust FES and FDG uptake, and had response at 3 months. (b) This patient has bone metastasis (solid arrow) without FES but with FDG uptake; progressive disease at 6 months. (Reproduced from [94].)